Xylem (NYSE:XYL) Price Target Raised to $147.00

Xylem (NYSE:XYL) had its target price raised by analysts at Oppenheimer from $142.00 to $147.00 in a research note issued on Friday, Benzinga reports. The firm presently has an “outperform” rating on the industrial products company’s stock. Oppenheimer’s target price points to a potential upside of 7.76% from the company’s current price.

A number of other brokerages have also commented on XYL. Raymond James upgraded shares of Xylem from an “underperform” rating to a “market perform” rating in a report on Thursday, January 4th. Robert W. Baird upped their price objective on Xylem from $151.00 to $155.00 and gave the stock an “outperform” rating in a research report on Friday. Mizuho boosted their target price on shares of Xylem from $110.00 to $135.00 and gave the stock a “neutral” rating in a report on Friday. Royal Bank of Canada upped their target price on Xylem from $140.00 to $145.00 and gave the company an “outperform” rating in a research report on Wednesday, February 7th. Finally, BNP Paribas assumed coverage on Xylem in a report on Tuesday, March 12th. They set an “outperform” rating and a $150.00 price objective for the company. Five equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $139.00.

Xylem Stock Performance

Shares of XYL traded up $0.42 during mid-day trading on Friday, hitting $136.41. The company’s stock had a trading volume of 92,043 shares, compared to its average volume of 1,171,682. The firm has a market capitalization of $33.07 billion, a PE ratio of 50.10, a price-to-earnings-growth ratio of 2.61 and a beta of 1.08. Xylem has a one year low of $87.59 and a one year high of $138.46. The stock’s 50-day moving average is $128.41 and its two-hundred day moving average is $114.89. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.30 and a current ratio of 1.76.

Xylem (NYSE:XYL) last released its quarterly earnings results on Thursday, May 2nd. The industrial products company reported $0.90 earnings per share for the quarter, beating analysts’ consensus estimates of $0.84 by $0.06. Xylem had a return on equity of 9.65% and a net margin of 8.27%. The firm had revenue of $2.03 billion during the quarter, compared to analysts’ expectations of $2 billion. During the same period last year, the firm posted $0.72 EPS. The business’s revenue was up 40.4% on a year-over-year basis. As a group, sell-side analysts anticipate that Xylem will post 4.13 EPS for the current year.

Insider Transactions at Xylem

In other news, CAO Geri-Michelle Mcshane sold 1,000 shares of the stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $122.89, for a total value of $122,890.00. Following the completion of the transaction, the chief accounting officer now owns 2,935 shares of the company’s stock, valued at $360,682.15. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CAO Geri-Michelle Mcshane sold 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $122.89, for a total transaction of $122,890.00. Following the sale, the chief accounting officer now directly owns 2,935 shares in the company, valued at $360,682.15. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Franz Cerwinka sold 2,408 shares of the stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $121.79, for a total transaction of $293,270.32. Following the sale, the senior vice president now directly owns 11,750 shares in the company, valued at approximately $1,431,032.50. The disclosure for this sale can be found here. Insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in Xylem by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 28,048,996 shares of the industrial products company’s stock worth $3,207,683,000 after buying an additional 187,847 shares in the last quarter. Morgan Stanley increased its position in shares of Xylem by 11.5% during the 3rd quarter. Morgan Stanley now owns 4,528,905 shares of the industrial products company’s stock valued at $412,267,000 after purchasing an additional 466,911 shares during the last quarter. Invesco Ltd. grew its position in Xylem by 35.1% during the 3rd quarter. Invesco Ltd. now owns 4,182,821 shares of the industrial products company’s stock worth $380,762,000 after acquiring an additional 1,086,102 shares during the last quarter. Royal Bank of Canada raised its holdings in Xylem by 10.6% in the 3rd quarter. Royal Bank of Canada now owns 3,408,200 shares of the industrial products company’s stock worth $310,249,000 after purchasing an additional 327,383 shares in the last quarter. Finally, Baillie Gifford & Co. grew its holdings in shares of Xylem by 2.3% during the 4th quarter. Baillie Gifford & Co. now owns 3,066,639 shares of the industrial products company’s stock worth $350,701,000 after acquiring an additional 69,619 shares during the period. Institutional investors own 87.96% of the company’s stock.

About Xylem

Xylem Inc, together with its subsidiaries, engages in the design, manufacture, and servicing of engineered products and solutions worldwide. It operates through four segments: Water Infrastructure, Applied Water, Measurement & Control Solutions, and Integrated Solutions and Services. The Water Infrastructure segment offers products, including water, storm water, and wastewater pumps; controls and systems; filtration, disinfection, and biological treatment equipment; and mobile dewatering equipment and rental services under the ADI, Flygt, Godwin, Sanitaire, Magneto, Neptune Benson, Ionpure, Leopold, Wedeco, and Xylem Vue brands.